Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy (2023)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3389/fimmu.2023.1183983

Publication URI: http://dx.doi.org/10.3389/fimmu.2023.1183983

Type: Journal Article/Review

Parent Publication: Frontiers in Immunology